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Chordomas are rare tumors of the bone with an
average incidence of 0.1 per 100,000 per year.1
Chordomas derive from remnants of the embryonic
notochord, which extends throughout the axial
skeleton. The incidence of distant metastases varies,
ranging between 3% and 50% among the different
series.2-4 The most common sites of metastases are
liver, lungs, and bones. Although skin may be often
involved because of direct extension from the
primary tumor or local recurrences, distant skin
metastasis from chordoma is an extremely rare
finding, with less than 20 cases reported in the
literature. We present here the unusual case of a
45-year-old woman with skin metastasis from a
sacral chondroid chordoma.
CASE REPORT
A 45-year-old woman had sacral chordoma
diagnosed in 2007. She initially complained of a
2-year history of lower back pain radiating to the
coccygeal and perianal region, which became
increasingly worse and accompanied by hypo-
esthesia of the left perianal area. By the end of
2007, computed tomography scan and magnetic
resonance imaging showed a large lobulated mass
extending from S2 to S5, invading the left gluteal
muscle, suggesting sacral chordoma. She underwent
partial sacrectomy in January 2008. The pathology
report revealed a white-greyish mass that on optical
microscopy showed a neoplastic proliferation of
cells gathered in nests separated by fibrous septa.
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m.sporadic cells bearing an eosinophilic cytoplasm
and no mitosis. The stroma presented a mixed
component with chondral characteristics. Immuno-
histochemistry was diffusely positive for pancytoker-
atin, vimentin, and S-100 protein and focally positive
for epithelial membrane antigen. Carcinoembryonic
antigen and HMB-45 findings were negative. These
findings were concordant with chondroid chordoma
with negative margins. Eleven months after surgery,
asymptomatic locoregional recurrence was found on
magnetic resonance imaging. The lesion was
completely excised. Pathologic findings confirmed
chordoma recurrence, and adjuvant radiotherapy
was administered. One year later, new locoregional
recurrence and soft tissue metastasis at the L4
level were observed. The lesions were deemed
unresectable, so systemic treatment with imatinib,
800 mg daily, was started. Six months later, new
progression with subcutaneous soft tissue mass at
the L4 level was noted. Treatment shifted to
sunitinib, 37.5 mg daily, but the disease progressed
3 months later with liver, bone, and lung metastases.
Third-line treatment with cisplatin, 25 mg/m2
intravenously weekly, and imatinib, 400 mg daily,
was initiated. She achieved stable disease for at
least 7 months. With extensive metastatic disease
by September 2013, she subsequently had a
firm, nontender, erythematous nodule measuring
2 3 2 cm on her left cheek (Fig 1).
Shewas referred to a dermatologist, and the lesion
was excised. Pathologic examination found
skin metastasis from chondroid chordoma, with
immunohistochemical characteristics consistentJAAD Case Reports 2016;2:63-6.
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Fig 1. Skin metastases from chondroid chordoma on the cheek and back.
Fig 2. Staining of skin metastasis from chondroid chordoma. A, Skin with many vacuolated
cells in the dermis. B, cells present a clear cytoplasm with some cells with eosinophilic
cytoplasm on a chondral stroma. Some of the cells present the characteristic physaliferous
cytoplasm. (A and B, Hematoxylin-eosin stain; original magnifications: A, 32; B, 310.)
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progression was observed after 7 months, and
treatment with imatinib and sirolimus was
commenced. Three months later, she experienced
disease progression, with 2 new skin lesions on
the chin and frontal area and 2 new lesions on the
back (Fig 1). Erlotinib, 150 mg daily, was started.
Although no significant toxicity was reported, dis-
ease progression was noted after 3 months of
treatment. Best supportive care was then offered.
The patient died 2 months later, 7 years after the
initial diagnosis.DISCUSSION
Chordomas are low-grade, slow-growing tumors
that typically remain silent until advanced stages of
the disease when they present with locally aggres-
sive behavior and clinical manifestations that vary
depending on their location. Despite an increase in
the last decades in the number of reports describing
skin involvement in chordomas, these have been
commonly related to direct invasion or locoregional
involvement, whereas distant skin metastases have
remained an extremely uncommon presentation in
these tumors. In a retrospective study in which
Fig 3. Immunohistochemistry staining. Skin metastasis from chordoma positive for
pancytokeratines (A), S100 (B), epithelial membrane antigen (C), and vimentin (D).
Table I. Differential diagnosis of chordoma
Primary tumors
d Low-grade (myxoid) chondrosarcoma
d Myxoid liposarcoma
d Parachordoma
d Clear cell sarcoma
d Myxopapillary ependymoma
d Chondroma
d Chondroid syringoma
d Melanocytic lesions with balloon cell morphology.
Metastatic tumors
d Mucinous cell adenocarcinoma
d Clear cell adenocarcinoma
d Signet ring cell adenocarcinoma
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skin involvement with only 1 presenting distant
skin metastasis.5 When present, a reddish, firm,
nontender nodule of variable size is the most
common appearance. Ulcerations may also be
present. The face or back is the most common initial
location, although scalp, trunk, and extremities
have also been reported.6-9 Although distant skin
metastases may be the first symptom of the disease,
they generally present as a clinical manifestation of
advanced disease, when metastases in other sites are
already present.
Histologically, chordomas may present as 3
different variants: classical, themost frequent variant,
chondroid, with cartilage-like tissue areas, and
dedifferentiated. All the previously reported cases
except one were classic variants of chordoma.2
The diagnosis may be challenging because of
the tumor’s histologic similarities with other chon-
droid lesions. Differential diagnosis includes primary
tumors or metastatic lesions containing a clear
cell or abundant mucin component (Table I).10
Immunohistochemical staining is useful and is char-
acterized by the tumor’s reactivity to epithelial
markers. Triple positivity to cytokeratins, vimentin,
and S-100 is a sensitive marker in the diagnosis of this
tumor, as it is present in 75% to100% of cases.11,12
These features are usually present in metastatic
lesions, although a loss of S-100 expression hasoccasionally been reported.6,8 Recently, brachyury,
a transcription factor that regulates the mesoderm
and notochord formation in humans, has emerged as
a novel biomarker to discriminate chordomas from
other chondroid lesions. Sensitivity and specificity
are very high and, when combined with CKs, can
increase up to 98% and 100%, respectively.13
Chordomas are locally aggressive tumors with
poor long-term prognosis and a natural history of
local recurrences. Classic chemotherapy shows
limited efficacy. Molecular profiling shows over-
expression of PDGFR-(platelet derived growth factor
receptor)-b, PDGFR-a and KIT receptors with some
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in combination with other drugs such as sirolimus or
cisplatin.14,15 Tyrosine kinase inhibitors like suniti-
nib have also shown some activity, and different
molecular pathways are currently under investiga-
tion as possible targets for new treatments.16
Despite its rarity, metastases should be considered
in the differential diagnosis when a new cutaneous
lesion appears in a patient with chordoma.
Immunohistochemical findings are crucial in the
diagnosis and are usually concordantwith the primary
tumor. A better understanding of the molecular
pathways of this disease may lead to improvements
in the management of this infrequent tumor.REFERENCES
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